SURMOUNT-5
2025
A Study of Tirzepatide Compared With Semaglutide in Participants With Obesity or Overweight
In 751 adults with obesity but without type 2 diabetes, tirzepatide reduced body weight at 72 weeks more than semaglutide (-20.2% vs -13.7%).
Result
difference-6.5P < 0.001
Also reported: Tirzepatide superior: waist circumference also fell more (-18.4 vs -13.0 cm).
- Subtopic
- GIP/GLP-1 RA
- Design
- Phase 3b, open-label, randomised active-controlled head-to-head trial
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ACC/AHA 2026 CKM
- Source
- Aronne LJ, et al. N Engl J Med. 2025;393(1):26-36.doi 10.1056/NEJMoa2416394
Discussion & critique
Open-label design (no placebo/blinding) and an efficacy endpoint of weight rather than CV outcomes. First head-to-head RCT positioning tirzepatide as the more potent option for pharmacologic weight management in obesity without diabetes.